Arrivals of the twice-yearly PrEP option in Eswatini and Zambia mark an important milestone in the goal of ending the…
– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase…